We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Randox Adiponectin Assay Gains CE Approval
Product News

Randox Adiponectin Assay Gains CE Approval

Randox Adiponectin Assay Gains CE Approval
Product News

Randox Adiponectin Assay Gains CE Approval


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Randox Adiponectin Assay Gains CE Approval"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

World-leading diagnostics firm Randox Laboratories has recently launched   a biochemistry Adiponectin assay. Testing adiponectin allows assessment of the risk of developing Type 2 diabetes and Cardiovascular Disease (CVD). In using Latex-Enhanced Immunoturbidimetric technology, Randox have brought a superior option for Adiponectin assessment to the clinical diagnostics market.

Adiponectin is a protein hormone produced and secreted exclusively by adipocytes. It regulates the metabolism of lipids and glucose, and influences the body's response to insulin. Adiponectin also has anti-inflammatory effects on the cells lining the walls of blood vessels. Low levels of Adiponectin therefore can be indicative of insulin resistance (leading to type 2 diabetes), and Cardiovascular Disease (CVD).  Low adiponectin levels have also been shown to correlate with increased likelihood of a woman developing gestational diabetes in pregnancy.

Randox also offers 2 levels of adiponectin controls as well as an adiponectin calibrator, delivering a complete testing package.

Speaking after the approval announcement, Randox Managing Director Dr Peter FitzGerald said,

“It is clear that in the 21st Century, increasing sedentary and deskbound lifestyles are driving chronic conditions such as diabetes and cardiovascular disease. 382 million people currently live with diabetes across the world and according to the International Diabetes Federation, this figure is predicted to rise by 55% by 2015. Adiponectin assesses an individual’s risk of developing diabetes, and allows resources and treatment to be focused on those patients most at risk. This highly targeted strategy should help to decrease the number of people becoming diabetic, while using resources most effectively.”

Advertisement